Semaglutide is a GLP-1 receptor agonist, which means that it mimics the action of a hormone in the body called glucagon-like peptide-1 (GLP-1)
When semaglutide was in shortage, that authority allowed compounders to fill the gap
Second, since January 2026, an FDA-approved oral semaglutide tablet (Wegovy pill) also offers a needle-free option - but that's a prescription pharmaceutical, not a supplement
Modalit d'uso e posologia
According to NICE guidance (NG28), the continuation of GLP-1 receptor agonist therapy in type 2 diabetes should be assessed after six months, with treatment continued only if there is a reduction in HbA1c of at least 11 mmol/mol (1%) and, where applicable, a weight loss of at least 3% of initial body weight
Maintenance & Optimization Weight stabilizes near goal